Glenview Trust’s Halozyme HALO Stock Holding History

Glenview Trust’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,740	Closed	-$274K	–	495
2025 Q3	$274K	Buy	+3,740	New	+$248K	﹤0.01%	441

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Glenview Trust's HALO Position: Q4 2025 in Review

Glenview Trust sold out of Halozyme (HALO) in Q4 2025, closing a stake of 3,740 shares — an estimated $274K sold.

Glenview Trust first reported a position in HALO in Q3 2025 and held it in 1 quarter. The position peaked at $274K in Q3 2025. 619 funds tracked by Wall St. Rank hold HALO as of Q4 2025.

Glenview Trust reported no remaining Halozyme position as of Q4 2025 after selling out during the quarter.
Glenview Trust sold 3,740 Halozyme shares in Q4 2025, an estimated $274K.
Glenview Trust first reported a position in Halozyme in Q3 2025 and held it in 1 quarter.
Glenview Trust's Halozyme position peaked at $274K in Q3 2025.
619 funds tracked by Wall St. Rank held Halozyme as of Q4 2025.

Based on Glenview Trust's 13F filing for Q4 2025, filed 9 Feb 2026.